Financial Performance - GeneDx grew revenues to $102.7 million, a 49% increase year-over-year[25] - Exome and genome test revenue grew to $85.9 million, a 69% increase year-over-year[25] - The company delivered an adjusted gross margin of 71%, up from 62% in the second quarter of 2024[25] - Adjusted net income was $15.0 million in the second quarter of 2025[25] - Cash, cash equivalents, marketable securities, and restricted cash totaled $135.5 million as of June 30, 2025[39] Volume and Market Share - Exome and genome volume grew 28% year-over-year in Q2 2025[34] - The mix share for exome and genome tests grew to 41%[34] Guidance - The company updated its full-year 2025 revenue guidance to $400 to $415 million, from $360 to $375 million[40] - The company expects growth in exome and genome revenue of 48% to 52%[40] - The company expects growth in exome and genome volume of 30%[40] - The company expects adjusted gross margin of 68% to 71%[40]

Financial Performance - Total revenue for the three months ended June 30, 2025, was $102.692 million, a 45.5% increase from $70.514 million in the same period of 2024[14] - Diagnostic test revenue reached $99.823 million for the three months ended June 30, 2025, compared to $69.439 million in the prior year, reflecting a 43.9% growth[14] - Gross profit for the six months ended June 30, 2025, was $129.378 million, up from $80.363 million in 2024, indicating a 60.9% increase[14] - The company reported a net income of $10.809 million for the three months ended June 30, 2025, compared to a net loss of $29.173 million in the same quarter of 2024[14] - Net income for the six months ended June 30, 2025, was $4,280,000, a significant improvement compared to a net loss of $49,412,000 for the same period in 2024[19] - Pro forma revenues for the three months ended June 30, 2025, were $103.2 million, compared to $72.1 million for the same period in 2024, reflecting a significant increase[49] - Pro forma net income for the three months ended June 30, 2025, was $11.1 million, a recovery from a net loss of $31.4 million in the same period of 2024[49] - Net income attributable to common stockholders for Q2 2025 was $10.8 million, compared to a loss of $29.2 million in Q2 2024, resulting in basic earnings per share of $0.38 versus a loss of $1.10[13] Expenses and Investments - Research and development expenses for the three months ended June 30, 2025, were $15.079 million, an increase from $10.902 million in 2024, representing a 38.1% rise[14] - Stock-based compensation expense for the six months ended June 30, 2025, was $11,796,000, compared to $2,657,000 for the same period in 2024[19] - The Company recorded $2.3 million and $4.5 million in depreciation and amortization expenses for the three and six months ended June 30, 2025, respectively[75][76] - The Company incurred $1.7 million and $4.2 million in purchases from Twist Biosciences for the three and six months ended June 30, 2025, respectively[79] - The Company recorded a depreciation and amortization expense of $11,869,000 for the six months ended June 30, 2025, compared to $10,466,000 in 2024[19] Assets and Equity - Total assets as of June 30, 2025, amounted to $463.863 million, up from $419.380 million at the end of 2024, showing a 10.6% increase[13] - Total stockholders' equity increased to $277.133 million as of June 30, 2025, compared to $245.247 million at the end of 2024, reflecting a 13.0% growth[13] - Cash, cash equivalents, and restricted cash at the end of the period were $75,110,000, an increase from $57,063,000 at the end of June 2024[19] - Cash and cash equivalents as of June 30, 2025, totaled $74.1 million, down from $85.2 million as of December 31, 2024[116] - Total cash, cash equivalents, and restricted cash amounted to $135.5 million as of June 30, 2025, compared to $142.2 million as of December 31, 2024[190] Acquisitions and Strategic Direction - The company plans to pursue a new strategic direction, including exiting certain business segments, which is expected to impact gross margins positively[11] - The acquisition of Fabric Genomics is anticipated to provide expected benefits, although specific financial impacts were not detailed[11] - The company acquired Fabric Genomics on May 5, 2025, enhancing its capabilities in genomics and diagnostics[22] - The Company completed the acquisition of Fabric Genomics for approximately $33.5 million, enhancing its AI capabilities in Next Generation Sequencing analysis[41] - The Company agreed to pay up to $10.5 million in contingent consideration based on Fabric Genomics achieving gross revenue of at least $6.0 million and a gross margin of at least 69% for the fiscal year ending December 31, 2025[67] Liabilities and Debt - The total financial liabilities as of June 30, 2025, were $5.828 million, an increase from $3.519 million as of December 31, 2024[57][58] - As of June 30, 2025, the total long-term debt, net of current portion, was $51.7 million, with scheduled maturities including $51.3 million due in 2028[80] - The Company entered into a Credit Agreement with Perceptive Credit Holdings IV, LP, providing a senior secured delayed draw term loan facility of up to $75.0 million, with an initial tranche of $50.0 million funded on October 27, 2023[71][81] - The Perceptive Term Loan Facility has a maturity date of October 27, 2028, with an interest rate of Term SOFR plus an applicable margin of 7.5%[83] Stock and Equity Compensation - The balance of common stock increased to 28,708,058 shares as of June 30, 2025, from 28,530,337 shares at March 31, 2025[16] - The Company issued 645,414 shares of Class A common stock to Perceptive in satisfaction of a cashless exercise of Initial Warrant Shares at an aggregate exercise price of $2.5 million[72][87] - The Company issued 150,000 shares of Class A common stock in the ATM offering during the first half of 2025, raising $13.8 million at an average price of $96.10 per share[118] - The Company recorded an aggregate reversal of stock-based compensation of $0.8 million during the six months ended June 30, 2025, due to forfeiture activities upon employee terminations[98] - The total fair value of restricted stock units vested during the six months ended June 30, 2025, was $7.1 million, with unrecognized stock-based compensation expense related to restricted stock units amounting to $41.1 million[108] Tax and Regulatory Matters - The effective tax rate for the three months ended June 30, 2025, was (2.3%), while for the six months it was 4.5%, compared to 0.6% and 0.5% for the same periods in 2024[112] - The Company is assessing the impact of the One Big Beautiful Bill Act (OBBBA) on its consolidated financial statements, which is expected to be reflected in the third fiscal quarter of 2025[114] Segment Performance - Total revenue for the GeneDx operating segment in Q2 2025 was $101.8 million, a significant increase from $68.9 million in Q2 2024, representing a growth of approximately 47.6%[121] - Adjusted gross profit for the GeneDx segment in Q2 2025 was $71.8 million, up from $42.4 million in Q2 2024, reflecting an increase of about 69.2%[121] - The GeneDx segment is the only reportable segment, focusing on pediatric and rare disease diagnostics, primarily through whole exome and genome sequencing[119] Cash Flow and Reserves - Cash provided by operating activities for the six months ended June 30, 2025, was $20,602,000, compared to cash used in operating activities of $20,918,000 for the same period in 2024[19] - The company experienced a net cash used in investing activities of $45,758,000 for the six months ended June 30, 2025[19] - As of June 30, 2025, the company's third-party payor reserves amounted to $17.6 million, up from $12.6 million as of December 31, 2024[56] - The fair value of total financial assets as of June 30, 2025, was $123.104 million, compared to $114.576 million as of December 31, 2024, reflecting an increase of approximately 7.5%[57][58]

Exhibit 99.1 GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights GAITHERSBURG, Md., July 29, 2025 — GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025. "Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth at scale and enabling us to reach more p ...

Core Insights - GeneDx Holdings Corp. has consistently surpassed earnings estimates, averaging a 202.27% beat over the last two quarters [1][2] - The company reported earnings of $0.28 per share against a consensus estimate of $0.11, resulting in a surprise of 154.55% for the last quarter [2] - For the previous quarter, earnings were $0.7 per share compared to an expected $0.2, delivering a surprise of 250.00% [2] Earnings Estimates and Predictions - Estimates for GeneDx Holdings have been trending higher due to its history of earnings surprises [5] - The stock has a positive Zacks Earnings ESP of +5.26%, indicating bullish sentiment among analysts regarding future earnings [8] - The combination of a positive Earnings ESP and a Zacks Rank of 2 (Buy) suggests a strong likelihood of another earnings beat in the upcoming report [8] Earnings ESP and Market Behavior - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7] - A negative Earnings ESP can reduce predictive power but does not necessarily indicate an earnings miss [9]

Core Insights - GeneDx Holdings Corp. is set to report its second-quarter 2025 results on July 29, with strong expectations based on previous performance and estimates [1][10] Financial Performance - The company reported first-quarter adjusted earnings of 28 cents per share, exceeding the Zacks Consensus Estimate by 154.55%, marking a consistent trend of earnings beats over the past four quarters with an average surprise of 145.82% [1] - The Zacks Consensus Estimate for second-quarter revenues is $84.7 million, indicating a 20.1% increase from the previous year, while the EPS estimate is 10 cents, reflecting a significant year-over-year increase of 190.9% [2] Estimate Revisions - Earnings estimates have increased by 11.1% to 10 cents in the last 30 days, indicating positive sentiment ahead of the earnings announcement [3] Growth Drivers - Revenue growth is anticipated to be driven by Exome and genome tests, with a notable 24% year-over-year increase in test volume during the first quarter, contributing to a 62% revenue increase [4] - The acquisition of Fabric Genomics is expected to enhance GeneDx's capabilities in AI-powered genomic interpretation, facilitating a more comprehensive approach to genomic medicine [5] - The launch of ultraRapid Whole Genome Sequencing is projected to provide faster diagnoses for neonatal and pediatric patients, further contributing to revenue growth [7] Operational Efficiency - The company achieved a 56% growth in adjusted gross profit from continuing operations in the first quarter, leading to a 69% increase in gross margin, with expectations of continued operational efficiency in the second quarter [8] Market Position - GeneDx's strong performance in pediatric neurology and new testing indications is likely to drive outpatient volume growth, positioning the company favorably in the market [9]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of GeneDx Holdings Corp due to allegations of materially misleading business information [1] Group 1: Legal Actions and Investigations - Shareholders who purchased GeneDx securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - A report by Grizzly Research accused GeneDx of committing widespread fraud, claiming that its growth is an illusion driven by fraudulent schemes [3] Group 2: Stock Performance - Following the allegations from Grizzly Research, GeneDx's stock price fell by $4.84, or 6.7%, closing at $67.18 per share on February 5, 2025 [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4]

Company Overview - GeneDx Holdings is a healthcare technology company that integrates AI and machine learning with clinical and genomic data, focusing on precision medicine and individualized patient care [7] - The company has a market capitalization of $2.29 billion and reported a revenue of $330 million with a net income of -$38.6 million for the trailing twelve months [6] Recent Financial Performance - GeneDx Holdings shares have appreciated by 141.5% over the past year as of July 11, 2025 [5] - The company reported a 42% year-over-year increase in revenue for the first quarter, driven by high volumes of exome and genome tests [9] - Revenue from exome and genome tests accounted for 82% of GeneDx's total Q1 revenue, with the net loss for the quarter shrinking to $6.5 million from $20 million in the prior-year period [10] Insider Activity - On July 11, 2025, Kevin Feeley, CFO of GeneDx Holdings, sold 5,278 shares, reducing his holdings to 3,392 shares, which represents approximately 0.01% of total shares outstanding [1][4] - This sale is consistent with Feeley's recent trading patterns, as it is near the median trade size for him over the last several quarters [3] Growth Catalysts - GeneDx has strong growth prospects, particularly following its acquisition of Fabric Genomics, which enhances its AI-driven test interpretations and expands its genomics testing portfolio [12] - The company is targeting a larger patient population by expanding testing to outpatient pediatrics, NICU patients, and newborns [11] - Management has raised its full-year revenue guidance to a range of $360 million to $375 million, up from the previous forecast of $350 million to $360 million [10]

Core Viewpoint - GeneDx Holdings Corp. is anticipated to report a year-over-year increase in earnings driven by higher revenues, with a consensus outlook suggesting a significant earnings surprise could impact its stock price in the near term [1][2]. Company Summary - The upcoming earnings report is expected to show quarterly earnings of $0.10 per share, reflecting a year-over-year increase of +190.9%. Revenues are projected to reach $84.7 million, which is a 20.1% increase from the same quarter last year [3]. - The consensus EPS estimate has been revised down by 7.81% over the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for GeneDx Holdings is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +5.26%. The company currently holds a Zacks Rank of 2, suggesting a strong likelihood of beating the consensus EPS estimate [12]. Earnings Surprise History - In the last reported quarter, GeneDx Holdings was expected to post earnings of $0.11 per share but actually delivered earnings of $0.28, resulting in a surprise of +154.55%. The company has beaten consensus EPS estimates in each of the last four quarters [13][14]. Industry Context - In the Zacks Medical Services industry, Revvity is expected to report earnings of $1.14 per share for the quarter ended June 2025, indicating a year-over-year decline of -6.6%. Revenue for Revvity is expected to be $711.27 million, up 2.8% from the previous year [18]. - Revvity's consensus EPS estimate has remained unchanged over the last 30 days, but a higher Most Accurate Estimate has led to an Earnings ESP of +0.88%. This suggests Revvity is also likely to beat the consensus EPS estimate, having done so in each of the trailing four quarters [19].

Core Viewpoint - DJS Law Group is investigating GeneDx Holdings Corp. for potential violations of securities laws, focusing on allegations of fraudulent activities and misleading statements made by the company [1][2]. Group 1: Investigation Details - The investigation is centered on whether GeneDx made false or misleading statements or failed to disclose material information relevant to investors [2]. - A report by Grizzly Research claims that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at manipulating Medicaid and Medicare programs to artificially inflate revenue [2]. - Allegations include that GeneDx inflated earnings through the unlawful practice of "code stacking," which allows billing for services that do not meet appropriate standards [2]. Group 2: Insider Trading Allegations - The report also alleges that CEO Katherine Stueland and CFO Kevin Feeley have routinely sold their shares upon vesting without participating in open market acquisitions, suggesting insider awareness of potential threats to the business [2]. Group 3: DJS Law Group's Focus - DJS Law Group aims to enhance investor returns through balanced counseling and aggressive advocacy, specializing in securities class actions and corporate governance litigation [2].

Post this SAN FRANCISCO, July 21, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to alleged false statements about its health intelligence platform called Centrellis. Current shareholders are encouraged to contact the firm. On June 23, 2025, Judge Vernon D. Oliver of the U.S. District Court for the District of Connecticut ruled that a securities fraud lawsuit against GeneDx, its CEO, and ...